C-YCQQFrontier Bio
tissue engineering, vascular grafts, human tissue models
replacementreplacingtissue engineered
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-YCQQ
C-YCQQC-YCQQtissue engineering, vascular grafts, human tissue models
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Frontier Bio tissue engineering, vascular grafts, human tissue models
Frontier Bio is a U.S. tissue-engineering startup pursuing two linked product lines: a patient-seeded, bioresorbable vascular graft intended for implantation and remodeling into a living blood vessel, and human tissue models such as lung and blood-brain-barrier/neural systems for preclinical testing. The central promise is plausible in concept and supported by repeated, fairly consistent company and interview claims, some partnership signals, and early preclinical/research-use positioning, but the evidence here is still weak on independent validation: most sources are company-controlled, interview-based, press-style, or investor-marketing materials, and the excerpts do not provide robust methods, sample sizes, peer-reviewed outcomes, or clinical data.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Frontier Bio — Early mechanism · Bottom quartile. Derived deterministically from 6 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic